The effect of soy isoflavones on steroid metabolism by Swart, Amanda C.. et al.
ORIGINAL RESEARCH
published: 11 April 2019
doi: 10.3389/fendo.2019.00229
Frontiers in Endocrinology | www.frontiersin.org 1 April 2019 | Volume 10 | Article 229
Edited by:
Damian G. Romero,
University of Mississippi Medical
Center, United States
Reviewed by:
Sylvie Babajko,
INSERM U1138 Centre de Recherche
des Cordeliers, France
Andrea Carranza,
National Council for Scientific and
Technical Research (CONICET),
Argentina
*Correspondence:
Stephen L. Atkin
sla2002@qatar-med.cornell.edu
†Joint senior authors
Specialty section:
This article was submitted to
Cellular Endocrinology,
a section of the journal
Frontiers in Endocrinology
Received: 13 January 2019
Accepted: 21 March 2019
Published: 11 April 2019
Citation:
Swart AC, Johannes ID,
Sathyapalan T and Atkin SL (2019)
The Effect of Soy Isoflavones on
Steroid Metabolism.
Front. Endocrinol. 10:229.
doi: 10.3389/fendo.2019.00229
The Effect of Soy Isoflavones on
Steroid Metabolism
Amanda C. Swart 1, Inge D. Johannes 1, Thozhukat Sathyapalan 2† and Stephen L. Atkin 3*†
1Department of Biochemistry, Stellenbosch University, Stellenbosch, South Africa, 2 Academic Diabetes, Endocrinology and
Metabolism, University of Hull, Hull, United Kingdom, 3 Research Department, Weill Cornell Medical College Qatar, Doha,
Qatar
Objective: This study is a post-hoc analysis of steroid hormones before and after
administration of pharmacological doses of soy isoflavones in a large cohort of men and
women from two independent studies. Isoflavones are reported to inhibit mineralo- and
glucocorticoid hormone production as well as reproductive steroids in vivo and in vitro.
We focused on cytochrome P450 17α-hydroxylase (CYP17A1) which catalyses the
production of dehydroepiandrosterone (DHEA), in the androgen biosynthesis pathway
to elucidate effects on sex steroids in vitro.
Design and Setting: Effects of soy isoflavones on steroid levels in two studies
comprising 400 patients were examined: 200 men (study 1; 3 months duration) and 200
postmenopausal women (study 2; 6 months duration), randomized to consume 15g
soy protein with 66mg isoflavones (SPI) or 15 g soy protein alone without isoflavones
(SP) daily. Effects of genistein and daidzein on steroid metabolism were determined in
vitro, in HEK293 cells expressing CYP17A1 and in the human adrenocortical carcinoma
H295R cell model.
Results: SPI decreased serum dehydroepiandrosterone sulfate (DHEAS) levels in both
men and women (P < 0.01), with decreased androstenedione (A4) (P < 0.01) in women
not observed in men (P < 0.86). Cortisol, cortisone, 11-deoxycortisol, aldosterone,
testosterone (T), or estradiol (E2) levels were unchanged. The dual hydroxylase and
lyase activity of CYP17A1, which catalyses the biosynthesis of androgen precursors,
and 3β-hydroxysteroid dehydrogenase (3βHSD2) were investigated in vitro. In transiently
transfected HEK293 cells, only the lyase activity was inhibited by both genistein, 20%
(P < 0.001) and daidzein, 58% (P < 0.0001). In forskolin-stimulated H295R cells DHEA
production was decreased by daidzein (P < 0.05) and genistein, confirming inhibition of
the lyase activity by the isoflavones.
Conclusion: In Vivo clinical data suggested inhibition of CYP17A1 17,20 lyase within
the adrenal in men and within the ovary and adrenal in females. This was confirmed
in vitro with inhibition of the lyase activity by both genistein and daidzein. In addition,
3βHSD2 was inhibited perhaps accounting for decreased A4 levels observed in females.
The decreased DHEAS and A4 levels together with the inhibition of the 17,20 lyase activity
of CYP17A1, may impact production of androgens in clinical conditions associated with
androgen excess.
ISRCTN number: ISRCTN55827330
ISRCTN number: ISRCTN 90604927
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INTRODUCTION
Dietary intake of isoflavones in Asian diets has been estimated
to be in the range of 30–50 mg/day of combined isoflavone
aglycone equivalents that are mainly genistein and daidzein (1,
2). Health effects of soy consumption have been reported for
protection against breast and prostate cancer (3–5), osteoporosis
(6), cardiovascular diseases (7, 8), and the alleviation of hot
flashes (9). This has led to the development of supplements
containing isoflavones and the fortification of foods with
soy isoflavones (10, 11). However, there are concerns that
soy may adversely affect thyroid function in susceptible
individuals (12–14).
We have shown that high-dose isoflavone intake, in
comparison with isoflavone-free soy, impairs thyroid function in
patients with type 2 diabetes (T2DM) (Study 1) (15) and also in
post-menopausal healthy women (Study 2) (16). Study 1 was a
randomized double-blind parallel study investigating the effect of
soy isoflavones on testosterone (T) serum concentrations in men
with T2DM; whereas study 2 was a double-blind randomized
parallel study investigating the effect of high dose isoflavone
intake on bone turnover markers in women within 2 years of
onset of menopause. The effect of soy isoflavones on other steroid
hormones, is not well-established.
Isoflavones have been reported to have an inhibitory action
on steroid pathways potentially impacting the biosynthesis
of estradiol (E2) and T, although this has not been observed
clinically. A study which undertook a meta-analysis of clinical
outcomes of effects of isoflavones on T, free T, and sex-
hormone binding globulin (SHBG), reported that neither
isoflavones nor soy protein effected these three parameters
significantly (17). However, 3β-hydroxysteroid dehydrogenase
type 2 (3βHSD2), which catalyses the production of sex
steroid precursors, has been reported to be inhibited by
isoflavones, together with cytochrome P450 21 hydroxylase
(CYP21A2). CYP21A2 catalyses the production of steroid
hormone intermediates in the adrenal (18, 19) thus potentially
impacting steroidogenesis (20, 21). A schematic of the relevant
steroid pathways is shown in Figure 1 in which cytochrome
P450 side chain cleavage (CYP11A1) catalyses the conversion
of cholesterol, the common precursor to all steroid hormones,
to pregnenolone (PREG). PREG is subsequently channeled
into the androgen pathway (15 pathway) by cytochrome P450
17α-hydroxylase (CYP17A1) via 17-hydroxypregnenolone
(17OHPREG) or into the mineralocorticoid pathway by
3βHSD2. In this pathway, the 3βHSD2 product, progesterone
(PROG), is converted by CYP21A2 and aldosterone synthase
(CYP11B2) via the intermediates, deoxycorticosterone and
corticosterone, to aldosterone. 17OHPREG is also converted
by 3βHSD2 to form 17OHPROG, which is ultimately
converted to cortisol by CYP21A2 and cytochrome P450
11β-hydroxylase (CYP11B1). 17OHPROG is also a product of
the hydroxylase activity of CYP17A1 in the conversion of PROG
(14 pathway). In humans, the conversion of 17OHPROG to
androstenedione (A4) is negligible with the latter produced
from dehydroepiandrosterone (DHEA) via the 15 pathway via
3βHSD2 (22). In the adrenal, DHEA is predominantly converted
to dehydroepiandrosterone sulfate (DHEAS), which is the most
abundant steroid produced at levels 30-fold higher than DHEA,
with the latter increasing ∼50-fold upon adrenocorticotropic
hormone (ACTH) stimulation (23).
A number of studies have reported that isoflavones inhibit
mineralo- and glucocorticoid hormone production as well as
reproductive steroids in vivo and in vitro (18–21). The present
study was therefore initiated to do a post-hoc analysis of steroid
hormones before and after administration of pharmacological
doses of soy isoflavones in a large cohort of men and women
from two independent studies. In order to elucidate the effects
of two isoflavone glycones, daidzein, and genistein, on steroid
pathways in vitro, we focused on CYP17A1 since the enzyme
catalyses the production of DHEA, the precursor to sex steroids
in steroidogenic tissue and to DHEAS in the adrenal. Firstly,
we investigated the CYP17A1 hydroxylase activity by assaying
the conversion of PROG and the CYP17A1 17,20 lyase activity
by assaying the conversion of 17OHPREG in the presence
of isoflavones in transiently transfected HEK293 cells, void
of interfering steroidogenic enzymes. This was followed by
further investigations into effects on the lyase activity in H295R
cells, a human adrenal cell model. These cells produce all
the steroids characteristic of the cortical zones which include
the mineralocorticoids, glucocorticoids and adrenal androgen
precursors. In addition, due to the expression of low levels of
17β-hydroxysteroid dehydrogenase (17βHSD) and cytochrome
P450 aromatase (CYP19A1), these cells produce T, estrone and
E2, albeit at low levels. SinceH295R cells are insensitive to ACTH,
forskolin was used to stimulate steroidogenesis and thus increase
the steroid flux toward DHEA. Forskolin, a diterpene, mimics the
actions of ACTH via the activation of adenyl cyclase pathways in
adrenal cells (24). In order to eliminate downstream conversion
of the steroids in the15 pathway, trilostane, a 3βHSD2 inhibitor
was added, blocking the conversion of PREG and 17OHPREG
in aldosterone and cortisol production respectively. The effects
of genistein and daidzein on DHEA production could therefore
be investigated under basal and stimulated conditions together
with the addition of 17OHPREG to analyse the lyase activity
of CYP17A1.
MATERIALS AND METHODS
In vivo Effects of Isoflavones on
Hormonal Parameters
Patients and Protocols
Study 1 involved 200 men aged between 45 to 75 years with
T2DM, low early morning total T concentrations (total T less
than the lower level of the reference range of 12 nmol/L) and
normal gonadotropins who participated in a randomized double-
blind parallel study investigating the effect of soy isoflavones
on serum T concentrations. They were randomized either to
consume 15 g soy protein with 66mg of isoflavones (SPI) per day
or 15 g soy protein alone without any isoflavones (SP) per day for
3 months in the form of snack bars (Figure 2A). Study 2 involved
200 healthy women within 2 years of the onset of menopause
who were recruited (16) to assess the impact of high dose soy
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FIGURE 1 | Steroid hormone biosynthesis in the mineralocorticoid, glucocorticoid, and sex steroid pathways. Production is catalyzed by steroidogenic enzymes
(boxed, shaded in gray) in the adrenal (broken gray line) and in steroidogenic tissue (broken black line). The conversion of 17-hydroxyprogesterone (17OHPROG) to
androstenedione (A4) by CYP17A1 in humans is negligible (broken gray arrow).
isoflavones on bone turnover markers (Figure 2B). Both studies
received ethical approval by the Research Ethics Committee (East
Yorkshire & North Lincolnshire Research Ethics Committee,
ref: 09/H1304/45 and 09/1304/45). Computer-generated block
randomization lists were performed by Essential Nutrition Ltd,
Brough, UK, who held the randomization codes for both studies.
The intervention consisted of a snack bar containing 7.5 g
isolated soy protein powder (Solcon F, Solbar Industries, Israel)
with 33mg of isoflavones (SPI) (Solgen 40, Solbar Industries,
Israel) given twice daily between meals (15 g soy protein &
66mg of isoflavones per day), or 7.5 g of the isolated soy
protein given twice daily (15 g soy protein per day without
isoflavones per day) as control (SP). The latter had an isoflavone
concentration of less than 300 parts per billion following serial
alcohol extraction by Dishman Ltd, India (16). The product
isoflavones were assayed by FERA, Sand Hutton, UK (16).
Analysis showed the composition of the dose materials to be
12% glycitein, 35% daidzein, and 54% genistein as aglycones.
Ninety percent of the isoflavones were in the primary glucoside
form, with the remaining 10% as aglycones, specifically malonyl
and acetyl glucosides. The snack bars were consumed twice
daily between meals (3 months for study 1 and 6 months
for study 2). The study bars were prepared and packaged
by Halo foods, Swindon, UK. Soy bars were identical and
had similar macronutrient content and a tasting panel had
determined that there was no discernible difference between the
two products.
Steroid hormone levels were quantified using liquid
chromatography tandem-mass spectrometry (LC-MS/MS)
(25). The isoflavones were extracted and analyzed from serum
by LGC, Fordham, Cambridgeshire, UK using isotope-dilution
FIGURE 2 | Flow diagram of participant details from recruitment to the end of
study 1 (A) and study 2 (B).
LC-MS/MS (26). LC-MS/MS was conducted using a Sciex 4000
QTRAP with separation achieved using a C18 column with
the mobile phase consisting of acetonitrile and water, both
containing acetic acid (15).
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In vitro Influence of Daidzein and Genistein
on Steroid Hormones
Materials
Pregnenolone (PREG), progesterone (PROG),
17-hydroxypregnenolone (17OHPREG), 17-
hydroxyprogesterone (17OHPROG), androstenedione (A4),
and dehydroepiandrostenedione (DHEA) were purchased
from Steraloids (Newport, USA). Deuterated steroids were
acquired from Cambridge isotopes (Andover, USA) and
included testosterone 1,2-D2 (D2-T; 98%), progesterone
2,2,4,6,6,17,21,21,21-D9 (D9-P4; 98%), and 4-androstene-3,17-
dione 2,2,4,6,6,16,16-D7, (D7-A4, 97%,). HEK293 cells were
purchased from American Type Culture Collection (Manassas,
USA) and H295R cells were a kind gift from Prof. WE. Rainey,
Ann Arbor, University of Michigan. The CYP17A1/pcDNA3.1
plasmid construct was gifted by Prof CE Flück (University
of Bern, Switzerland). NucleoBond R© Xtra Maxi plasmid
DNA isolation kits were purchased from Macherey-Nagel
(Düren, Germany). Corning R© CellBIND R© Surface 12- and
24-well tissue culture plates were acquired from Corning R©
Life Sciences (NY, USA) whilst XtremeGene HP R© DNA
transfection reagent was purchased from Roche Diagnostics
(Manheim, Germany). Penicillin-streptomycin, fetal bovine
serum (FBS) and trypsin-EDTA were supplied by Thermo Fisher
Scientific (Waltham, USA). Methyl tert-butyl ether (MTBE),
analytical-grade methanol and formic acid were purchased
from Sigma-Aldrich (St. Louis, MA, USA). Dulbecco’s modified
Eagle’s Medium (DMEM), DMEM/F12 and gentamicin were
purchased from Invitrogen/Gibco (Grand Island, New York,
USA). Cosmic calf serum (CCS) was supplied by HyClone R©,
Thermo Scientific (South Logan, Utah, USA). The Acquity
UPC2 BEH C18 column was obtained from Waters Corporation
(Milford, USA). FOODFRESH CO2 was supplied by Afrox (Cape
Town, South Africa). Daidzein and genistein were purchased
from Sigma-Aldrich (St. Louis, MA, USA). All other chemical
reagents were of the highest quality and supplied by reputable
scientific distributors.
Methods
Cells were cultured in a stable environment at 37◦C, 5%
CO2 and 90% relative humidity. HEK239 cells were cultured
in DMEM supplemented with 10% FBS and 1% penicillin-
streptomycin; H295R cells in DMEM/F12, supplemented with
L-glutamine, 15mM HEPES, pyridoxine, 1.125 g NaHCO3/L,
1% penicillin streptomycin, 0.01% gentamicin, and 10% CCS.
Cells were verified to be mycoplasm free and cell viability
not compromised by the addition of the isoflavones (10µM).
Experimental procedures were carried out once cells were
80% confluent and had reached a minimum of three to
five passages.
Confluent HEK293 cells were seeded into 24 well plates at
a density of 2 × 105 cells/mL, 0.5 mL/well, and transiently
transfected after 24 h with 0.5 µg CYP17A1/pcDNA3.1 or
pCIneo (negative control without DNA insert) per well according
to manufacturer’s instructions. Cells were incubated for 48 h after
which media was replaced with experimental media (culture
media containing 0.1% FBS) to which steroid substrates (PROG
and 17OHPREG) were added with and without 10µM genistein
or daidzein. Steroid conversion was assayed by collecting media
aliquots (500 µL) at specific time intervals followed by steroid
extraction (27).
Confluent H295R cells were seeded into 12 well plates (4
× 105 cells/mL, 1 mL/well) and incubated for 48 h after which
media was replaced with experimental media (growth medium
containing 0.1% CCS) with and without 10µM forskolin and
10µM trilostane. Cells were incubated for a further 12 h and
media replaced with experimental media (i) with and without
isoflavones (10µM) to assay CYP17A1 activity under basal
conditions and (ii) containing 1µM 17OHPREG with and
without isoflavones (10µM) to assay lyase activity in forskolin-
stimulated cells in which inhibition of 3βHSD2 activity by
trilostane prohibited downstream steroid conversion. Steroid
metabolism was assayed after 48 h by collecting media aliquots
(500 µL) and extracting steroid metabolites.
Steroids were extracted by liquid/liquid extraction as
previously described (27). Briefly, organic solvent extraction was
carried out using a ratio of 1:3 (v/v) media to MTBE after the
addition of 100 µL internal standard mix consisting of D9-P4,
D7-A4, D2-T (1.5 ng each), prior to extraction. Samples and
standards were vortexed at 800 RPM for 5min and incubated at
−80◦C for an hour. The liquid organic phase was transferred to
test tubes and dried under nitrogen at 55◦C. The dried residue
(samples and standards) were resuspended in 150 µL 50%
methanol and analyzed using Ultra-Performance convergence
chromatography-tandem mass spectrometry (UPC2-MS/MS).
The steroid metabolites were separated using an Acquity
UPC2 BEH C18 column (2.1 × 100mm, 1.7µm particle size)
with an Acquity UPC2 system (Waters Corporation, Milford,
USA). Quantitative mass spectrometric detection was carried
out using a Xevo TQ-S triple quadrupole mass spectrometer
(Waters, Milford, USA). The mobile phase consisted of liquid
CO2 modified with methanol. A 2.5min linear gradient from 4 to
25% methanol was used to separate the steroids using a constant
flow rate of 2.0 mL/min.
Statistical Analysis
This was a post-hoc exploratory analysis of two in vivo studies
to understand the impact of high dose isoflavones on steroid
concentrations and hence a priori power analyses were not done
for changes in steroid concentrations.
Baseline continuously distributed data is presented as median
(25/75th centiles); categorical data by n (%). Within-group
differences (difference between 12 week/24 week values and
baseline values) are shown for each treatment group separately
by a mean and a standard deviation (SD). Between-group
comparisons were performed using the independent sample t-
test. The t-test assumes equal variance between groups. For
all statistical analyses, a two-tailed P < 0.05 was considered
to indicate statistical significance. Statistical analyses were
performed using the STATA statistical computer package
(StataCorp 2013. Stata Statistical Software: StataCorp LP, USA).
GraphPad Prism (version 7.0) software (GraphPad Software,
San Diego, California) was used for statistical analysis of in
vitro data. Experiments were carried out in triplicate with
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results depicting the mean value ± SEM, with 3 independent
experiments conducted, or mean value ± SD. Statistical
significance was determined using a two-way ANOVA followed
by a Dunnett’s multiple comparison test. Probability (P) values
lower than 0.05 were considered statistically significant.
RESULTS
Analysis of in vivo Effects on
Hormonal Parameters
The demographics for study 1 (men; median (25/75th centiles);
BMI and age control 31.6 (29.2, 35.0) and 52.0 years (50.0, 55.0),
BMI and age active preparation 31.8 (28.8, 34.7) and 52.0 years
(50.0, 55.0). Study 2 (median (25/75th centiles); BMI and age
control 24.6 (22.7, 28.4) and 52.0 years (50.0, 55.0), BMI and
age active preparation 26.3 (24.3, 30.7) and 52 years (49, 56).
In Study 1, there was a significant decrease in DHEAS with SPI
supplementation (Table 1, P < 0.01) whereas in study 2 there
was a significant decrease in both DHEAS and A4 with SPI
supplementation (Table 2, P < 0.01). No changes were observed
in basal levels of T, E2, cortisol, cortisone, A4 (men only),
17OHPROGor aldosterone (Tables 1, 2). No stimulation tests for
adrenal function were undertaken.
Analysis of in vitro Effects on Steroid
Hormone Production
The influence of the isoflavones on CYP17A1 activity was
ascertained in transiently transfected HEK293 cells and in the
H295R adrenal cell model. Although pharmacological doses
of isoflavones of 66mg per day resulted in circulating levels
of 127 and 70 nmol/L daidzein and 434 and 338 nmol/L
genistein in males and females respectively, uptake by target
tissue remains unknown as does accumulation and elimination
of isoflavones. Previous reports showed significant inhibition of
both 3βHSD2 and CYP21A2 at 12.5µM; and of 3βHSD2 at lower
concentrations of 1µMgenistein and 3.1µMdaidzein (18). Since
these concentrations would potentially modulate steroidogenesis
in both the adrenal and steroidogenic tissue, we conducted our in
vitro assays with 1 and 10µM genistein and daidzein.
The hydroxylase activity was firstly assayed in the presence
of the isoflavones using PROG as substrate since CYP17A1
does not readily convert the hydroxylated intermediate to
A4 in humans. In HEK293 cells transiently transfected with
CYP17A1, without and in the presence of daidzein and
genistein, the conversion of PROG to 17OHPROG (Figure 3A)
showed that neither isoflavone inhibited the hydroxylase activity
with ∼0.2µM substrate remaining after 24 h. Neither of the
isoflavones inhibited the conversion of PREG to 17OHPREG
(data not shown). In order to assay the 17,20 lyase activity
in the 15 pathway, the conversion of 17OHPREG to DHEA
(Figure 3B) was assayed. Both isoflavones inhibited the lyase
activity significantly with daidzein exhibiting a greater inhibitory
effect. While ∼70% 17OHPREG was converted to DHEA after
24 h in the absence of isoflavones, only ∼33% was converted to
DHEA in the presence of daidzein (P< 0.0001) and∼55% in the
presence of genistein (P < 0.001). The assay was also conducted
at lower concentrations (1µM) of isoflavones which also resulted
in significant inhibition of the lyase activity (Figure 3C).
The influence of daidzein and genistein on the 15 pathway
was subsequently investigated in the adrenal H295R cell model.
Basal endogenous steroid levels are depicted in Figure 4A
showing the addition of isoflavones resulting in 17OHPREG
and DHEA levels increasing significantly by ∼3.8- and ∼4.85-
fold, respectively. Basal levels were∼0.035µMwith 17OHPREG
increasing to 0.06µM and DHEA to 0.14 and 0.19µM in
the presence of daidzein and genistein, respectively. Treatment
with forskolin and trilostane (Figure 4B) increased basal
levels ∼12-fold with 17OHPREG and DHEA levels increased
to ∼0.47µM. The addition of daidzein and genistein did
not change 17OHPREG levels; however, DHEA levels were
decreased, approaching significance. We subsequently assayed
the conversion of 1µM 17OHPREG under these conditions
(Figure 4C). After 48 h, 17OHPREG and DHEA were detected
at 0.78 and 0.5µM respectively, and in the presence of trilostane
and forskolin, 17OHPREG remained unchanged with only
daidzein significantly lowering DHEA levels to 0.34 µM.
DISCUSSION
The data show that dietary SPI supplementation modulated the
androgen biosynthesis pathway in vivo showing that in both
men and women DHEAS levels were significantly decreased
by the SPI preparation compared to soy alone, suggesting
that the isoflavones may impact either on the steroidogenic
1
5 pathway or the sulphation/desulfation of DHEA. Neither
daidzein nor genistein influenced levels of mineralocorticoids or
glucocorticoids significantly in the study subjects. Aldosterone
levels did not change significantly while cortisol levels remained
comparable together with the precursor steroids in both study
groups remaining unchanged. The inactivation of cortisol was
also not influenced with cortisol:cortisone ratios unchanged after
consumption of isoflavones (6.4 in women and 6 in men).
Corroborating previous reports, (17) T, free T and SHBG levels
were also not influenced by the isoflavones, suggesting that the
influence of the isoflavones on these steroids is not clinically
significant. However, A4 levels were significantly decreased in
women consuming isoflavones. In women, A4 is the product of
DHEA and the precursor steroid of T, both products of the ovary
and adrenal (Figure 1). As mentioned previously, the adrenal
is the primary site of DHEAS biosynthesis in men and women
and most of the DHEA produced is converted to DHEAS. A4
may also be biosynthesized in the desulfation of DHEAS via
the subsequent conversion of DHEA to A4, or de novo from
cholesterol in both the adrenal and steroidogenic tissue such as
the ovary and gonads. It was therefore essential to elucidate the
effect isoflavones have on the androgen biosynthesis pathway
in vitro.
In sex steroid biosynthesis pathway PREG is channeled toward
DHEA via 17OHPREG, catalyzed by CYP17A1, prompting us
to investigate the influence of the isoflavones on CYP17A1 as
the enzyme is at the branchpoint of adrenal steroidogenesis
catalyzing the production of mineralocorticoids, glucocorticoids,
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TABLE 1 | Comparison of hormonal parameters levels with active (66mg isoflavones) and control (0mg isoflavones) preparations in 171 men treated for 12 weeks.
Active SPI n = 85 Control SP n = 86 Difference
Parameter Baseline 12 weeks Baseline 12 weeks Active Control (95% CI)
p-value
Total testosterone (nmol/L) 9.83 ± 0.21 11.34 ± 0.36 9.22 ± 0.23 10.33 ± 0.30 1.51 ± 0.25 1.10 ± 0.27 (−0.31–1.14) 0.26
% free testosterone 2.66 ± 0.56 2.63 ±0.54 2.73 ± 0.63 2.78 0.03 ± 0.04 0.05 ± 0.07 0.22
Absolute free testosterone (nmol/L) 0.21 ± 0.05 0.24 ± 0.06 0.20 ± 0.05 0.23 ± 0.06 0.03 ± 0.06 0.03 ± 0.05 0.80
Androstenedione (nmol/L) 2.1 ± 0.09 2.3 ± 0.1 2.0 ± 0.09 2.1 ± 0.9 −0.12 ± 0.08 −0.05 ± 0.9 (−0.15–0.31) 0.52
17hydroxyprogesterone (nmol/L) 2.1 ± 0.13 2.2 ± 0.11 2.0 ± 0.09 2.0 ± 0.09 −0.08 ± 0.11 −0.06 ± 0.07 (−0.25–0.30) 0.86
SHBG (nmol/L) 32.32 ± 1.38 32.01 ± 1.53 31.65 ± 1.50 30.26 ± 1.40 −0.30 ± 0.71 −1.34 ± 0.59 (0.81–2.89) 0.27
FSH (iu/L) 7.89 ± 0.70 8.16 ± 0.71 7.27 ± 0.50 7.33 ± 0.53 0.27 ± 0.17 0.07 ± 0.12 (−0.21–0.61) 0.34
LH (iu/L) 4.42 ± 0.32 4.76 ± 0.31 4.26 ± 0.25 4.43 ± 0.28 0.34 ± 0.12 0.16 ± 0.15 (−0.20–0.55) 0.35
Estradiol (pmol/L) 85.01 ± 2.94 87.3 ± 2.83 88.91 ± 2.69 89.32 ± 2.84 2.29 ± 2.64 0.41 ± 2.43 (−5.24–9.0) 0.60
DHEA (nmol/L) 4.0 ± 0.4 4.1 ± 0.4 3.3±0.3 3.3 ± 0.2 −0.11 ± 0.22 0.06 ± 0.23 (−0.49–0.82) 0.6
DHEAS (umol/L) 2.93 ± 0.20 2.76 ± 0.17 2.69 ± 0.18 2.87 ± 0.19 −0.26 ± 0.07 0.18 ± 0.07 (−0.57–0.16) 0.01
Cortisol (nmol/L) 360 ± 11 375 ± 12 363 ± 13 392 ± 12 −12.7 ± 12.2 −28.0 ± 12.6 (−50.1–19.4) 0.38
Cortisone (nmol/L) 55.9 ± 1.2 58.1 ± 1.3 55.1 ± 1.2 75.7 ± 1.2 2.1 ± 1.1 2.2 ± 1.1 (−3.1–2.8) 0.9
Aldosterone (pmol/L) 108 ± 8 134 ± 10 147 ± 16 156 ± 20 27 ± 11 12 ± 14 (−21–53) 0.4
FSH, follicle stimulating hormone; LH, luteinising hormone; DHEAS, dehydroepiandrostenedione-sulfate; SHBG, sex hormone binding globulin.
TABLE 2 | Comparison of hormonal parameters levels with active (66mg isoflavones) and control (0mg isoflavones) preparations in 120 women treated for 26 weeks.
Active Control Difference
Parameter Baseline 26 weeks Baseline 26 weeks Active Control (95% CI)
p-value
Total testosterone
(nmol/L)
0.71 (0.3) 0.67 (0.27) 0.68 (0.32) 0.66 (0.3) 0 0.02 −0.02 (−0.09,0.03) 0.39
Androstenedione (nmol/L) 4.1 (2.1) 2.2 (1.5) 3.8 (2.8) 3.4 (2.9) −1.9 −0.2 −2.0 (−2.8, −1.2) < 0.01
17hydroxyprogesterone (nmol/L) 2.0 ± 0.09 2.1 ± 0.19 2.1 ± 0.11 2.1 ± 0.06 −0.09 ± 0.10 −0.02 ± 0.05 (−0.26–0.32) 0.92
SHBG (nmol/L) 56.5 (25) 52.7 (24.3) 56.6 (26.2) 53 (22.2) −3.8 −3.4 −0.4 (−5.5,4.6) 0.86
FSH (iu/L) 77.5 (27.9) 79.8 (34.4) 70.3 (31) 73.8 (33.3) 2.4 3.2 −6 (−15.2,3.1) 0.19
LH (iu/L) 34.1 (12.4) 35.5 (13.1) 33.1 (14.2) 35.3 (14.6) 1.2 3 −2.8 (−6.8,1.1) 0.16
Estradiol (pmol/L) 78.1 (32.9) 97.9 (89.7) 109.9 (113) 111.8 (122) 22 −4.3 26.4 (−19.5,2.4) 0.25
DHEAS (umol/L) 2.8 (1.5) 1.4 (1.3) 2.6 (2.1) 2.5 (1.3) −1.3 −0.22 −1.16(−1.77, −0.95) < 0.01
Cortisol (nmol/L) 331 345 365 349 21 16 (−37–45) 0.84
Cortisone (nmol/L) 56.4 55.9 58.3 56.7 1.4 2.0 (−22.5–79.1) 0.27
11 deoxycortisol (nmol/L) 0.5 ± 0.04 0.57 ± 0.06 0.70 ± 0.11 0.75 ± 0.13 0.07 0.05 (−0.25–0.2) 0.81
Aldosterone (pmol/L) 157 ± 13 171 ± 16 165 ± 18 176 ± 20 14 11 (−38–39) 0.98
FSH, follicle stimulating hormone; LH, luteinising hormone; DHEAS,dehydroepiandrostenedione-sulfate; SHBG, sex hormone binding globulin.
and sex steroids. Inhibition of the hydroxylase and lyase
activity of CYP17A1 would channel steroid metabolites into
the mineralocorticoid pathway. Inhibition of the dual activity,
would increase the flux toward mineralocorticoid production
as has been shown with the enzyme’s inhibition by abiraterone
in the treatment of prostate cancer resulting in not only
suppressed androgen production, but also hypertension and
hypokalemia (28). Inhibition of the lyase activity only, would
result in a decrease in the biosynthesis of androgens, channeling
the steroid flux toward the mineralo- and glucocorticoid
pathways. In the adrenal as well as in steroidogenic tissue
CYP17A1 catalyses the 17α-hydroxylase of PROG and PREG
to their hydroxyl intermediates. The subsequent 17,20 lyase
of 17OHPREG only yields DHEA in the 15 pathway. Data
clearly show that while the hydroxylase activity was not
affected (Figure 3A) the lyase activity was inhibited significantly
(Figure 3B). Previous studies had reported that neither daidzein
nor genistein inhibited CYP17A1 (19). This study however, did
not investigate the hydroxylase and 17,20 lyase activities as
individual reactions.
The inhibition of the lyase activity of CYP17 by the
isoflavones was investigated further in the H295R adrenal model
to determine effects on the 15 pathway in the presence of
competing enzymes viz 3βHSD2, SULT2A1, and 17βHSD. In
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FIGURE 3 | Assay of CYP17A1 hydroxylase and lyase activity in transiently transfected HEK293 cells in the presence of isoflavones. (A) conversion of 1µM PROG to
17OHPROG; (B) and (C) conversion of 1µM 17OHPREG to DHEA with substrate only (solid line) and in the presence of 10µM daidzein (..........) and 10µM genistein
(–.. –..). Data was analyzed by a two-way ANOVA, followed by a unpaired t-test. Results are expressed as the mean ± SEM (n = 3, ****P < 0.0001).
FIGURE 4 | Assay of CYP17A1 hydroxylase and lyase activity in the 15 pathway in H295R cells in the presence of 10µM daidzein and 10µM genistein after 48 h. (A)
basal endogenous steroid levels without and in the presence of isoflavones; (B) endogenous steroid levels in forskolin-stimulated cells in the presence of trilostane, a
3βHSD inhibitor, without and in the presence of isoflavones; and (C) the addition of 1µM 17OHPREG to forskolin-stimulated cells, in the presence of trilostane,
without and in the presence of isoflavones. Data was analyzed by a two-way ANOVA, followed by a Dunnett’s multiple comparison test. Results are expressed as the
mean ± SD (n = 3, *P < 0.05, **P < 0.01, ****P < 0.0001).
the presence of both isoflavones, 17OHPREG and DHEA levels
increased indicating the inhibition of 3βHSD2 activity, impacting
steroid metabolism in the mineralocorticoid, glucocorticoid, and
androgen pathways. Both daidzein and genistein have been
shown to be competitive inhibitors of 3βHSD2 with daidzein
shown to be a competitive inhibitor of CYP21A2 as well (19),
which would lead to a decrease in downstream metabolites
in the three pathways as has also been reported by other
groups (29–31). Subsequent to these studies, it was shown
that the presence of 10µM daidzein and genistein in H295R
cells stimulated with forskolin to mimic the action of ACTH,
increased PREG and DHEA levels significantly, corroborated
by our study. The authors attributed these changes, together
with the A4 and 17OHPROG levels decreasing significantly,
to the inhibition of 3βHSD2 only (32). It is possible that the
increased 17OHPREG and DHEA levels could be due to the
inhibition of 3βHSD2 and CYP21A2 increasing these precursor
steroids being shunted in the 15 pathway as is shown in our
data. On the other hand, higher DHEA levels may also be
due to the inhibition of 17βHSD5 which catalyses the further
conversion of DHEA to androstenediol in the adrenal. Inhibition
of the reductive activity of the enzyme by the isoflavones has
been reported with DHEA as substrate –daidzein exhibited
an IC50 at 10µM and genistein IC50 at 1µM (33). With
DHEA being converted predominantly to DHEAS in the adrenal,
inhibition of sulfotransferase (SULT2A1) activity may thus also
be contributing to DHEA levels. Such inhibition would result
in lower DHEAS levels which may account for our in vivo
findings. However, it has been reported that neither daidzein
nor genistein inhibit SULT2A1 at levels as high as 25µM (34).
The decreased DHEAS levels detected in our study in both
women and men would probably not be due to the inhibition
of adrenal production of DHEAS, but rather the modulation
of the steroid shunt in the 15 pathway. Since the adrenal
is an important source of androgen production in females,
the inhibitory effect of the isoflavones on the lyase activity of
CYP17A1 in the pathway and subsequent inhibition of 3βHSD2,
may account for the decreased A4 levels in women. It is also
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interesting to note that in women the decreased DHEAS levels
were 2-fold lower than those of the control group and, while A4
levels in males were not affected by the isoflavones, they were
comparable to the suppressed A4 levels detected in women after
26 weeks.
The modulation of DHEAS levels by isoflavones is complex
and analysis of the mechanism/s impacting the biosynthesis and
the metabolism of the conjugated steroid are not fully resolved.
Potentially contributing to DHEAS levels is the availability of
the DHEA precursor steroid in the 15 pathway determined
by the activity of CYP17A1 and by the subsequent metabolism
of DHEA by 17βHSD and 3βHSD2. In vivo DHEA levels
were not affected in our study. While genistein and daidzein
do not inhibit SULT2A1, other SULT isoforms, expressed in
the liver and kidney which also sulfonate DHEA may be
inhibited by these isoflavones, thus potentially accounting for
the decreased in vivo DHEAS levels that were detected. While
SULT2A1 is also abundantly expressed in the liver as well
as in the intestine and kidney (35), it has been reported to
be induced in the presence of genistein, mediated via the
liver X receptor as was shown in the Hep G2 liver cell
model (36). These findings suggest that this isoflavone would
thus potentially increase DHEAS production. Furthermore, the
daidzein sulfoconjugates, daidzein-4
′
-O-sulfate and daidzein-
7, 4
′
-di-O-sulfate are potent inhibitors of sterol sulfatase and
both conjugates, but not daidzein, have been shown to inhibit
the hydrolysis of DHEAS. In addition, neither conjugates nor
daidzein have been shown to inhibit sulfotransferase of DHEA
(30). These factors thus suggest that isoflavones would rather
contribute to the stimulation of DHEAS production and not
to the reduction thereof. While genistein and daidzein inhibit
steroidogenic enzymes modulating steroidogenesis, the fine
balance maintained between the steroid sulfotransferases and
sulfatases may be perturbed by the two isoflavonoids that may
account for our findings. Genistein and daidzein are both
conjugated in vivo with SULT1A1, 1A2, 2A1, and 1E1, all capable
of sulfonating genistein and daidzein at C4
′
and C7 (37), with
their sulfonated derivative having been detected in circulation
after soy milk dietary supplementation (38). Modulation of
DHEAS levels would be dependent on free isoflavone levels
as maintained by sulfotransferases and sulfatases activities in
steroidogenic tissue, in the liver and kidney, as well as by
the competitive inhibition of the aforementioned enzymes by
genistein and daidzein. Even though we have shown that
free daidzein and genistein levels were detected at 0.07 and
0.34µM (in females) and 0.125 and 0.43µM (in males) in
circulation, their accumulation in target tissue and intracellular
levels together with sulfonated levels, whichwould determine and
contribute to physiological effects, remain unknown and yet to
be explored.
These data clearly indicate that while 17,20 lyase activity
is significantly inhibited, T and other androgens were largely
unaffected. This would suggest that the impact is marginal and
therefore ingestion of isoflavones is safe in healthy individuals.
However, 17,20 lyase deficiency although rare, is recognized
and associated with androgen abnormalities, hypertension,
hypokalaemia, and fertility issues and a partial deficiency
would theoretically be exacerbated by isoflavone ingestion (39,
40). In addition, it is possible that these isoflavones may
interfere with the availability of cholesterol thus impacting
steroidogenesis. Daidzein and genistein have been shown
to suppress cellular cholesterol biosynthesis significantly in
HepG2 cells, while also lowering the cellular esterification of
cholesterol. It is possible that these isoflavones may therefore
lower the availability cholesterol in the H295R cells potentially
contributing to decreased steroid levels in the 15 pathway
since the conversion of cholesterol to PREG is the rate-limiting
step in steroidogenesis (41). Basal PREG levels were however
very low (≤10 nM). Of interest is a subsequent study which
reported that daidzein and genistein both increase mRNA
transcripts encoding enzymes involved in cholesterol and lipid
metabolism (42).
In conclusion, the in vivo clinical data suggest that there
was modulation of the 15 pathway with potential inhibition
of the 17,20 lyase activity within the adrenal in men and
within the ovary and adrenal in the females, while the in
vitro data confirmed that both genistein and daidzein did
indeed inhibit the 17,20 lyase activity of CYP17A1, though
this is unlikely to impact clinically. In addition, these data
confirmed the inhibition of 3βHSD2 by daidzein and genistein,
though again this may not be clinically significant in practice.
However, taken together, the effects of these isoflavones—the
decreased in vivo DHEAS and A4 levels and inhibition of
the 17,20 lyase activity of CYP17A1, impacts the production
of precursor androgens contributing to the pool of active
androgens, potentially relevant to clinical conditions associated
with androgen excess.
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